Results 201 to 210 of about 675,123 (288)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. [PDF]

Front Endocrinol (Lausanne), 2019
Gadelha M, Bex M, Colao A, Pedroza García EM, Poiana C, Jimenez-Sanchez M, Yener S, Mukherjee R, Bartalotta A, Maamari R, Raverot G.   +10 more
europepmc   +1 more source

Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. [PDF]

Oncologist, 2019
Kiesewetter B, Duan H, Lamm W, Haug A, Riss P, Selberherr A, Scheuba C, Raderer M.   +7 more
europepmc   +1 more source

Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells

Frontiers in Pharmacology
Valentina Rossi, Erika Di Zazzo, Giovanni Galasso, Caterina De Rosa, Ciro Abbondanza, Antonio A. Sinisi, Lucia Altucci, Antimo Migliaccio, Gabriella Castoria   +8 more
doaj   +1 more source

Nucleaire geneeskunde: Schijn of werkelijkheid? [PDF]

, 1992
Krenning, E.P. (Eric)
core  

Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † [PDF]

, 2017
Knigge, U., Kwekkeboom, D., Perren, A., Öberg, K.   +3 more
core  

Somatostatin and its analogs in the management of postoperative pancreatic fistulas: A comprehensive review. [PDF]

World J Gastrointest Surg
Lazaridou L, Dimaki A, Vakalou K, Zervas V, Papadopoulos P, Koumarelas KE, Christodoulidis G.   +6 more
europepmc   +1 more source

Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome [PDF]

, 2017
Anthony, LB, Banks, P, Bergsland, E, Caplin, ME, Gable, J, Hudgens, S, Kulke, MH, Lapuerta, P, Oberg, KE, Pavel, ME, Yang, QM   +10 more
core   +1 more source

Acromegaly: Treatment with somatostatin analogs

, 2016
Karavitaki, N, Wass, J
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Somatostatin and its Analogs

Current Drug Targets, 2016
Somatostatin (SST) is a cyclic hormone-release inhibitory peptide that has high binding affinity to all of its five SST receptors (SSTRs). SST negatively regulates cell proliferation and the release of multiple hormones via activation of its cognate receptors.
Lichun, Sun, David H, Coy
openaire   +3 more sources

Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression

Current Molecular Medicine, 2013
The pharmacological effects (i.e., inhibition of endocrine secretion and cell proliferation) mediated by the hormone somatostatin (SRIF) are derived from its universal high-affinity binding to five different G proteincoupled receptors (GPCRs), named sst1-5.
Ruscica M, ARVIGO, MARICA, Steffani L, FERONE, DIEGO, Magni P.   +4 more
openaire   +5 more sources